Zynerba Pharmaceuticals, Inc.
NASDAQ: ZYNE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Armando Anido MBA
- Employees
- 25
- Headquarters
- Devon, United States
- IPO year
- 2015
- Market cap
- $70.1M
- Website
- https://www.zynerba.com
Loading ZYNE…
Loading profile data…Frequently asked questions about ZYNE
What does Zynerba Pharmaceuticals, Inc. (ZYNE) do?
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade...
Where does ZYNE trade?
Zynerba Pharmaceuticals, Inc. (ZYNE) trades on the NASDAQ Global Market.
What sector is ZYNE in?
Zynerba Pharmaceuticals, Inc. (ZYNE) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Zynerba Pharmaceuticals, Inc.?
Armando Anido MBA is the chief executive officer of Zynerba Pharmaceuticals, Inc. (ZYNE).
Where is Zynerba Pharmaceuticals, Inc. headquartered?
Zynerba Pharmaceuticals, Inc. is headquartered in United States.
Does ZYNE pay a dividend?
Zynerba Pharmaceuticals, Inc. (ZYNE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZYNE go public?
Zynerba Pharmaceuticals, Inc. (ZYNE) completed its initial public offering in 2015.